VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AFGE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
AFGEAmerican Financial Group, Inc.
$15.93$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksAFGEFinancials

American Financial Group, Inc. (AFGE) Financials

23Y historyFree accessUpdated daily

Revenue growth has exhibited cyclical volatility, shifting from a 14.3% expansion in 2024Q1 to a 3.5% contraction by 2025Q4, despite maintaining a strong 81.6% combined ratio in the most recent quarter.

AFGE Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03
Revenue8.08B8.17B8.01B7.45B6.81B6.23B5.58B5.97B6.99B6.8B6.45B6.28B5.65B5.02B4.72B4.75B4.5B0294.1M344.1M364.7M414.99B342.42B266.65B
Revenue Growth %-0.22%2.05%7.49%9.43%9.36%11.62%-6.61%-14.52%2.76%5.41%2.76%11.11%12.61%6.4%-0.72%5.63%--100%-14.53%-5.65%-99.91%21.19%28.42%-
Medical Costs & Claims1.06B4.39B000000-161M-64M-46M134M-62M-74M404M363M378M462.6M463M549.9M463.8M477.65B519.9B447B
Medical Cost Ratio %13.12%53.68%0%0%0%0%0%0%-2.3%-0.94%-0.71%2.13%-1.1%-1.47%8.57%7.64%8.41%-157.43%159.81%127.17%115.1%151.83%167.64%
Gross Profit2.87B3.79B8.01B7.45B6.81B6.39B5.58B5.97B7.15B6.87B6.5B6.14B5.71B5.09B4.31B4.39B4.12B0-168.9M-205.8M-99.1M-477B-496.06B-180.36B
Gross Margin %35.45%46.32%100%100%100%102.67%100%100%102.3%100.94%100.71%97.87%101.1%101.47%91.43%92.36%91.59%--57.43%-59.81%-27.17%-114.94%-144.87%-67.64%
Gross Profit Growth %--52.73%7.49%9.43%6.52%14.59%-6.61%-16.45%4.15%5.65%5.74%7.56%12.2%18.09%-1.71%6.51%-100%17.93%-107.67%99.98%3.84%-175.04%-
Operating Expenses623M2.71B41M36M36M41M47M47M825M776M690M627M4.95B4.26B4.1B363M3.43B462M463M549M463M477.65B1.19B447B
OpEx / Revenue %7.71%33.19%0.51%0.48%0.53%0.66%0.84%0.79%11.8%11.41%10.69%9.99%87.61%84.85%87.02%7.64%76.27%-157.43%159.55%126.95%115.1%0.35%167.64%
Depreciation & Amortization42M86M000187M00210M107M134M134M-730M-771M-474M192M214M198M220M194M167M213.03B174.22B176.86B
Combined Ratio %20.83%86.87%0.51%0.48%0.53%0.66%0.84%0.79%9.5%10.47%9.98%12.12%86.52%83.38%95.59%15.28%84.68%-314.86%319.35%254.13%230.2%152.18%335.28%
Operating Income2.5B1.07B7.97B7.42B6.77B1.1B5.53B5.93B728M955M968M884M730M771M474M560M689M530M195M413.1M428M207.84B403.45B348.46B
Operating Margin %30.95%13.13%99.49%99.52%99.47%17.73%99.16%99.21%10.42%14.04%15%14.08%12.92%15.36%10.05%11.79%15.32%-66.3%120.05%117.36%50.08%117.82%130.68%
Operating Income Growth %--86.54%7.46%9.48%513.59%-80.04%-6.66%714.15%-23.77%-1.34%9.5%21.1%-5.32%62.66%-15.36%-18.72%30%171.79%-52.8%-3.48%-99.79%-48.49%15.78%-
EBITDA2.54B1.16B7.97B7.42B6.77B1.29B5.53B5.93B938M1.06B1.1B1.02B000752M903M728M415M607.1M595M420.87B577.67B525.32B
EBITDA Margin %31.47%14.18%99.49%99.52%99.47%20.73%99.16%99.21%13.42%15.62%17.08%16.21%0%0%0%15.83%20.08%-141.11%176.43%163.15%101.42%168.7%197.01%
Interest Expense84M80M76M76M85M94M88M68M62M85M77M74M73M71M85M85M78M04M31M31M28.05B32.41B36.39B
Non-Operating Income1.81B-80M7.97B7.42B6.77B-325M5.53B5.93B-161M-64M-46M134M-18M4M-138M-83M-78M-348.9M-190.9M-297.1M37.2M240.53B402.78B11.06B
Pretax Income1.11B1.07B1.12B1.07B1.12B1.33B339M634M639M724M787M565M626M689M537M560M689M812M315M638M697M356.81M589.54M301.01B
Pretax Margin %13.79%13.08%14.03%14.4%16.49%21.44%6.08%10.61%9.14%10.65%12.2%9%11.08%13.73%11.39%11.79%15.32%-107.11%185.41%191.12%0.09%0.17%112.89%
Income Tax236M231M237M221M225M254M25M143M122M247M119M195M220M236M135M240M266M282M115M225M235M115.84B186.09B-47.45B
Effective Tax Rate %21.17%21.61%21.09%20.6%20.04%19.03%7.37%22.56%19.09%34.12%15.12%34.51%35.14%34.25%25.14%42.86%38.61%34.73%36.51%35.27%33.72%32465.93%31565.23%-15.77%
Net Income879M842M887M852M898M1.39B732M897M530M475M649M352M452M471M488M320M423M530M200M413M462M240.97B403.45B348.46B
Net Margin %10.87%10.3%11.07%11.43%13.19%22.32%13.12%15.02%7.58%6.98%10.06%5.61%8%9.39%10.35%6.74%9.41%-68%120.02%126.68%58.07%117.82%130.68%
Net Income Growth %10.01%-5.07%4.11%-5.12%-35.4%89.89%-18.39%69.25%11.58%-26.81%84.38%-22.12%-4.03%-3.48%52.5%-24.35%-20.19%165%-51.57%-10.61%-99.81%-40.27%15.78%-
EPS (Diluted)10.5510.0810.5710.0510.5312.628.219.865.855.297.333.944.975.165.093.113.834.531.713.353.843048.115.394489.60
EPS Growth %10.71%-4.64%5.17%-4.56%-16.56%53.72%-16.73%68.55%10.59%-27.83%86.04%-20.72%-3.68%1.38%63.67%-18.8%-15.45%164.91%-48.96%-12.76%-99.87%56451.21%-99.88%-
EPS (Basic)-10.0810.5710.0610.5512.708.259.985.965.417.474.024.975.165.093.163.874.571.753.513.843099.925.484523.75
Diluted Shares Outstanding83.3M83.5M83.9M84.8M85.3M85.6M89.2M91M90.6M89.8M88.5M89.4M91M91.2M95.9M102.9M110.5M117M116.7M123.2M120.31M79.06M70.27M77.61M

Key Metrics

Growth RegimeMixed
ProfitabilityStrong
Balance SheetFortress
Cash FlowRobust
Top Statement Risk

Social inflation casualty exposure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Exhibits Cyclical Volatility

As reported in recent financial statements, AFGE's revenue growth has fluctuated significantly, moving from a peak of 14.3% in 2024Q1 to a contraction of 3.5% by 2025Q4, suggesting that the firm's decentralized underwriting model is highly sensitive to shifting market pricing cycles and competitive pressures.

The inconsistent top-line performance indicates a disciplined, albeit reactive, approach to premium volume where the firm appears willing to sacrifice growth to maintain underwriting standards. Investors should monitor whether this volatility reflects a strategic withdrawal from softening niche markets or a broader loss of competitive positioning against more aggressive specialty peers.

Underwriting Discipline Drives Profitability Outperformance

Based on the provided figures, AFGE maintained a combined ratio of 81.6% in 2025Q4, which, according to industry standards, signifies robust underwriting profitability that effectively insulates the firm from the volatility inherent in the broader property and casualty insurance market.

The ability to sustain such low combined ratios suggests that the firm's specialized business units are successfully pricing risk above expected loss costs. This margin profile appears to be a core competitive advantage, allowing the company to generate consistent underwriting profit even when premium growth remains stagnant.

Reserve Volatility Masks Underlying Performance

According to the quarterly data, the reported loss ratios have exhibited extreme swings, including negative values in early 2024, which suggests that prior-year reserve development is significantly distorting the current-period income statement and complicating the assessment of true, ongoing underwriting profitability.

These anomalous loss ratios warrant further investigation, as they may indicate aggressive reserve releases that artificially inflate net income. Analysts should be cautious in extrapolating current earnings power without adjusting for these non-recurring accounting adjustments that appear to mask the underlying claims environment.

Casualty Exposure Risks Future Earnings

While the firm reports strong headline profitability, the concentration in specialty casualty lines, as noted in institutional research, may leave the company vulnerable to social inflation and rising litigation costs that are not yet fully reflected in the current, historically low loss ratio metrics.

The reliance on niche casualty segments implies a latent risk that legal settlement trends could rapidly erode current underwriting margins. Investors should monitor whether the firm's reserve adequacy is sufficient to withstand a potential long-tail claims environment that often characterizes these specialized insurance lines.

AFGE — Frequently Asked Questions

Quick answers to the most common questions about buying AFGE stock.

What was American Financial Group, Inc.'s (AFGE) revenue in 2025?

For fiscal year 2025, American Financial Group, Inc. (AFGE) reported total revenue of $8.17B. This represents a 96.9% decline compared to $266.65B in 2003.

Is American Financial Group, Inc. (AFGE) profitable?

American Financial Group, Inc. (AFGE) is profitable, generating $842.0M in net income for the fiscal year ending 2025 with a net profit margin of 10.3%.

What is American Financial Group, Inc.'s operating profit margin?

American Financial Group, Inc. (AFGE) reported an operating income of $1.07B, resulting in an operating profit margin of 13.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is American Financial Group, Inc.'s gross profit and gross margin?

American Financial Group, Inc. (AFGE) generated $3.79B in gross profit for the year, representing a gross profit margin of 46.3%. This demonstrates the company's core pricing power and production efficiency.